ASH 2018 | Melflufen and dex with bortezomib/daratumumab for myeloma: OP-104 study

VJHemOnc is committed to improving our service to you

Enrique Ocio

Enrique Ocio, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain, discusses the Phase I/II OP-104 ANCHOR trial (NCT03481556) assessing the use of melflufen, an alkylating peptide, and dexamethasone in combination with either bortezomib or daratumumab in relapsed/refractory multiple myeloma (MM). Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Ocio discusses the encouraging efficacy, in terms of response rates and safety, of these combinations, with early signs of activity seen after only 1 cycle of therapy.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter